Evidence map›Paper›PMID 31938163›Full record

ArticleInternational journal of clinical and experimental pathology2018

High expression of Capn4 is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma.

Xianxian Wu, Hongdian Zhang, Chuangui Chen, Lei Gong, Yalei Wang, Xiaolei Zhu, Haitong Wang, Zhentao Yu

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. FBXL18 increases cell proliferation and reduces cell radiosensitivity in esophageal squamous cell carcinoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xianxian WuDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin, China.
Hongdian ZhangDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin, China.
Chuangui ChenDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin, China.
Lei GongDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin, China.
Yalei WangDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin, China.
Xiaolei ZhuDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin, China.
Haitong WangDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin, China.
Zhentao YuDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin, China.
Tianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calpain small subunit1 (Capn4) is present in various cancer types and is implicated in tumor metastasis. However, the role of Capn4 in esophageal squamous cell cancer (ESCC) has not been elucidated. In this study, immunohistochemistry was conducted to detect Capn4 expression and localization in 155 ESCC tissues and in 35 adjacent normal esophageal mucosal tissues. Following knockdown of Capn4 in esophageal cancer cells using RNA interference, we detected the migration and invasion ability of cells. The role of Capn4 on prognosis was evaluated using univariate and multivariate analysis in 155 ESCC patients. The immunohistochemistry results showed that Capn4 was highly expressed in ESCC tissues compared with normal peritumor esophageal tissues, and Capn4 overexpression was significantly related to tumor size (P = 0.027), tumor invasion depth (P = 0.019), and lymph node metastasis (P = 0.011). Knockdown of Capn4 drastically reduced migration and invasion of ESCC cells. Based on the results of the univariate analysis, patients with higher Capn4 had a poor prognosis. Through multivariate analysis, we found that Capn4 was an independent prognostic factor for overall survival in ESCC. These findings suggest that Capn4 overexpression contributes to the aggressive progression of ESCC and functions as a prognostic marker for patients with ESCC.

Indexed as

Capn4ESCCimmunohistochemistryprognosissiRNA

Identifiers

PMID31938163
PMCPMC6957994
OpenAlexW3028193628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.